VSTM Verastem, Inc.

1.87
0  -1%
Previous Close 1.89
Open 1.89
Price To book 0.97
Market Cap 69.18M
Shares 36,992,000
Volume 114,577
Short Ratio 0.45
Av. Daily Volume 385,176

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1b/2 trial initiated 1H 2016
Duvelisib and venetoclax
Relapsed or refractory CLL, small lymphocytic lymphoma, iNHL or aggressive NHL cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
Phase 3 data due mid-2017.
Duvelisib - DUO
Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
VS-6063
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem
  2. Verastem to Present at the 16th Annual Needham Healthcare Conference
  3. Data on Verastem’s Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
  4. Verastem Reports Year-End 2016 Financial Results
  5. Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights
  6. Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference
  7. Verastem to Present at the 29th Annual ROTH Conference
  8. Verastem to Present at 19th Annual BIO CEO & Investor Conference
  9. Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer
  10. Verastem Announces Executive Leadership Appointments and Changes
  11. Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
  12. Infinity (INFI) Reports Narrower-than-Expected Loss in Q3
  13. HC Wainwright Issues $5 Target for Verastem (VSTM)
  14. Verastem Reports Second Quarter 2016 Financial Results
  15. Verastem to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
  16. Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer

SEC Filings

  1. EFFECT - Notice of Effectiveness 17779486
  2. CT ORDER - Confidential treatment order 17766987
  3. DEF 14A - Other definitive proxy statements 17753949
  4. S-3 - Registration statement under Securities Act of 1933 17726981
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17709985
  6. 8-K/A (Amend) - Current report 17523251
  7. 10-Q - Quarterly report (Sections 13 or 15(d)) 161978471
  8. 8-K - Current report 161966301
  9. 10-Q - Quarterly report (Sections 13 or 15(d)) 161812926
  10. 8-K - Current report 161713158